Pfizer CEO says 2023 will be ‘transition year’ as it sees drop in COVID sales

Click to play video: 'Pfizer’s COVID-19 bivalent vaccine targeting Omicron subvariants get green light in Canada'
Pfizer’s COVID-19 bivalent vaccine targeting Omicron subvariants get green light in Canada
Canada's Health Minister Jean-Yves Duclos and chief public health officer Dr. Theresa Tam announced Friday that Health Canada has approved Pfizer's bivalent vaccine targeting Omicron. The bivalent booster dose will target both the original strain of COVID-19 and the two dominant BA.4 and BA.5 subvariants of the Omicron strain – Oct 7, 2022

Pfizer Inc on Tuesday forecast a bigger-than-expected drop in sales of its COVID-19 vaccine and treatment for 2023, intensifying investor concerns over demand for the products as governments cut orders and work through inventories.

Chief Executive Albert Bourla said that 2023 should be a “transition year” for Pfizer’s COVID products, before potentially returning to growth in 2024.

Pfizer’s total annual sales crossed the $100 billion mark for the first time in 2022, driven by the more than $56 billion in sales of its COVID-19 vaccine and Paxlovid antiviral treatment. It expects total 2023 revenue of $67 billion to $71 billion.

“We are building on a significant capital position that we know how to deploy to create growth,” Bourla told analysts and investors on conference call. “We are building an R&D engine that is more productive than ever.”

Story continues below advertisement

The company launched five new products last year and hopes to introduce as many as 14 more over the next year and a half,
including a vaccine for respiratory syncytial virus (RSV) and an mRNA flu vaccine.

Pfizer shares were down slightly at $43.53. The stock had tumbled 15 per cent this month, through Monday’s close.

The latest health and medical news emailed to you every Sunday.

Citi analyst Andrew Baum said the company is struggling to escape its dependence on COVID drugs.

“We see little here to change our cautious view on Pfizer’s ex-COVID business,” Baum said in a research note.

The decline in COVID-related revenue is not the only headwind Pfizer is facing.

The U.S. drugmaker will lose patent protections for some big-selling drugs after 2025, including cancer treatment Ibrance
and arthritis drug Xeljanz, and has said it expects to lose $17 billion in annual sales between 2025 and 2030 due to patent expirations.

Click to play video: 'Health Canada approves Pfizer-BioNTech bivalent Omicron vaccine'
Health Canada approves Pfizer-BioNTech bivalent Omicron vaccine

Pfizer has turned to acquisitions such as its $5.4 billion buyout of Global Blood Therapeutics Inc and its $11.6 billion purchase of migraine drugmaker Biohaven to bolster its pipeline of future products.

Story continues below advertisement

Citi’s Baum said he expects Pfizer will use the spike in revenue from its COVID products to “intensify and upscale” its efforts to buy other companies or new products to fill its pipeline.

Excluding COVID-related sales, Pfizer expects 2023 revenue to grow seven per cent to nine per cent.

Pfizer developed its COVID-19 vaccine with German partner BioNTech, and the companies split the profits. Pfizer forecast 2023 sales of $13.5 billion for their vaccine, below analysts’ estimates of $14.4 billion, and projected $8 billion in Paxlovid sales, short of Wall Street’s expectation of $10.33 billion.

Bourla said the company expects to start selling its COVID vaccine Comirnaty through commercial channels in the United
States in the second half of 2023, rather than selling the shots directly to the government. After that transition, the company hopes to roughly quadruple the U.S. price of the vaccine.

Analysts and investors have been looking for clarity on China demand for Paxlovid, where the drug is only covered by the country’s broad healthcare insurance plan until late March.

Pfizer said its current 2023 forecast for sales does not assume any revenue from China after April 1, but Bourla said the
company expects to offer Paxlovid in the private market there thereafter.

Story continues below advertisement

“There is still an opportunity for a market in China which could be meaningful” outside of the country’s main insurance channels, said BMO Analyst Evan Seigerman.

(Reporting by Manas Mishra and Bhanvi Satija in Bengaluru and Michael Erman in New Jersey; Editing by Jonathan Oatis and Bill Berkrot)

Sponsored content